Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC – Targeted Oncology
|
Immunotherapy Overtakes Targeted Therapy as First-Line Standard of Care for mRCC
Targeted Oncology An extension in overall survival (OS) with the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) has completely changed the standard of care for patients with metastatic renal cell carcinoma (mRCC), Thomas Powles, MD, MBBS, MRCP, told audience … |
